This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).
GSKNegative Net Change EWPositive Net Change VRTXPositive Net Change GMNegative Net Change MSCINegative Net Change LINNegative Net Change
biotechnology industrial-products medical-devices
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
SNYNegative Net Change NVONegative Net Change AMGNNegative Net Change GILDNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
by Zacks Equity Research
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
NVSNegative Net Change NVONegative Net Change INCYNegative Net Change LGNDPositive Net Change
biotechnology biotechs
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
CRSPNegative Net Change KALAPositive Net Change ALLOPositive Net Change DRMAPositive Net Change
biotechnology medical
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
ACADNegative Net Change AXSMNegative Net Change CRSPNegative Net Change ALLOPositive Net Change
biotechnology medical
Should You Buy Consolidated Edison (ED) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Buy Stocks for April 21st
by Zacks Equity Research
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
WORNegative Net Change SIEGYPositive Net Change RYINegative Net Change ANVSNegative Net Change ACLXPositive Net Change
biotechnology medical
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
CRSPNegative Net Change KALAPositive Net Change ALLOPositive Net Change VYNEPositive Net Change
biotechnology medical
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
by Zacks Equity Research
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
PFENegative Net Change ADMAPositive Net Change CRSPNegative Net Change ALLOPositive Net Change
biotechnology gene-editing medical
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
CRSPNegative Net Change MDGLPositive Net Change KALAPositive Net Change ALLOPositive Net Change
biotechnology medical
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
by Zacks Equity Research
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.
GSKNegative Net Change MRKNegative Net Change MRNANegative Net Change MDGLPositive Net Change PCVXPositive Net Change
biotechnology biotechs
Best Momentum Stocks to Buy for April 19th
by Zacks Equity Research
LRMR, VRTV and PLL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 19, 2023.
PLLNegative Net Change VRTVPositive Net Change LRMRPositive Net Change
biotechnology
New Strong Buy Stocks for April 19th
by Zacks Equity Research
SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.
PLLNegative Net Change SIGANegative Net Change VRTVPositive Net Change RYINegative Net Change LRMRPositive Net Change
biotechnology pharmaceuticals
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
by Zacks Equity Research
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.
PFENegative Net Change NVONegative Net Change LGNDPositive Net Change PCVXPositive Net Change
biotechnology biotechs pharmaceuticals
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge
by Zacks Equity Research
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
CRSPNegative Net Change KALAPositive Net Change ALLOPositive Net Change GMDAPositive Net Change
biotechnology medical
Bristol Myers (BMY), TSVT Application for Abecma Accepted
by Zacks Equity Research
Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.
BMYNegative Net Change NVONegative Net Change LGNDPositive Net Change
biotechnology biotechs pharmaceuticals
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
by Zacks Equity Research
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
CRSPNegative Net Change HGENNegative Net Change KALAPositive Net Change ALLOPositive Net Change
biotechnology medical
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate
by Zacks Equity Research
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.
TEVANegative Net Change KALAPositive Net Change ALLOPositive Net Change ALVOPositive Net Change
biotechnology medical
Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer
by Zacks Equity Research
Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was accepted by the FDA.
NVONegative Net Change MRKNegative Net Change LGNDPositive Net Change
biotechnology pharmaceuticals
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
by Zacks Equity Research
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
CRSPNegative Net Change KALAPositive Net Change ALLOPositive Net Change
biotechnology medical
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
by Zacks Equity Research
Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
CRSPNegative Net Change KALAPositive Net Change ALLOPositive Net Change PBLANo Net Change
biotechnology medical
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
MRNANegative Net Change IFRXPositive Net Change KALAPositive Net Change
biotechnology pharmaceuticals
KALA Up on Fast Track Designation to Lead Ocular Candidate
by Zacks Equity Research
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
NVONegative Net Change LGNDPositive Net Change KALAPositive Net Change
biotechnology biotechs pharmaceuticals
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
by Zacks Equity Research
Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.
AZNPositive Net Change MRKNegative Net Change FUSNPositive Net Change ALLOPositive Net Change
biotechnology medical oncology-screening
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
by Zacks Equity Research
MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer.
REGNNegative Net Change NVONegative Net Change LGNDPositive Net Change MAIANegative Net Change
biotechnology biotechs pharmaceuticals